1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in Mexico

Generics in Mexico

  • January 2017
  • -
  • MarketLine
  • -
  • 29 pages

Summary
Generics in Mexico industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Mexico
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Mexico
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Mexico generics market with five year forecasts by both value and volume

Synopsis
Essential resource for top-line data and analysis covering the Mexico generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
- What was the size of the Mexico generics market by value in 2016?
- What will be the size of the Mexico generics market in 2021?
- What factors are affecting the strength of competition in the Mexico generics market?
- How has the market performed over the last five years?
- How large is Mexico's generics market in relation to its regional counterparts?

Key Findings
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Mexican generics market is expected to generate total revenues of $6.3bn in 2016, representing a compound annual growth rate (CAGR) of 13.7% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 6.5% between 2012 and 2016, to reach a total of 90.3% of total pharma volume in 2016.

The Mexican generics market is set to continue to grow, as generics will play a key part in the government's healthcare modernization while keeping public spending costs under control.

Table Of Contents

Generics in Mexico
Table of Contents
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Apotex, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: Mexico generics market value: $ billion, 2012-16(e)
Table 2: Mexico generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Mexico generics market geography segmentation: $ billion, 2016(e)
Table 4: Mexico generics market value forecast: $ billion, 2016-21
Table 5: Mexico generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Apotex, Inc.: key facts
Table 7: Sandoz International GmbH: key facts
Table 8: Teva Pharmaceutical Industries Limited: key facts
Table 9: Teva Pharmaceutical Industries Limited: key financials ($)
Table 10: Teva Pharmaceutical Industries Limited: key financial ratios
Table 11: Mexico size of population (million), 2012-16
Table 12: Mexico gdp (constant 2005 prices, $ billion), 2012-16
Table 13: Mexico gdp (current prices, $ billion), 2012-16
Table 14: Mexico inflation, 2012-16
Table 15: Mexico consumer price index (absolute), 2012-16
Table 16: Mexico exchange rate, 2012-16

List of Figures
Figure 1: Mexico generics market value: $ billion, 2012-16(e)
Figure 2: Mexico generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Mexico generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Mexico generics market value forecast: $ billion, 2016-21
Figure 5: Mexico generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Mexico, 2016
Figure 7: Drivers of buyer power in the generics market in Mexico, 2016
Figure 8: Drivers of supplier power in the generics market in Mexico, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Mexico, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Mexico, 2016
Figure 12: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 13: Teva Pharmaceutical Industries Limited: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.